GlassScriptPhysician profile
Ronald Edwin Brown
NPI 1477191237
$2,621.73
in general payments reported to CMS, 2019-2025
32 companies · $939 in 2025
The $939 reported for 2025 was more than what 79% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $489 · 2024: $1,193 · 2025: $939.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,153 · Education: $469.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,152.70 |
| Education | $469.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $565.11 | 2023-2025 | Darzalex, Tecvayli, Talvey |
| Astrazeneca Pharmaceuticals LP | $259.60 | 2023-2025 | Enhertu, Imfinzi, Lynparza |
| Astellas Pharma US INC | $201.66 | 2024-2025 | Padcev |
| Novartis Pharmaceuticals Corporation | $194.85 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $120.08 | 2024-2025 | Opdivo |
| Incyte Corporation | $110.98 | 2023-2025 | Monjuvi, Jakafi |
| Pharmaessentia USA Corporation | $99.93 | 2024 | Besremi |
| Genzyme Corporation | $98.05 | 2024 | |
| Glaxosmithkline, LLC. | $95.44 | 2023-2025 | Ojjaara, Blenrep |
| Eisai INC. | $79.37 | 2024-2025 | |
| Sobi, INC | $77.81 | 2023-2024 | |
| Celgene Corporation | $76.99 | 2024-2025 | Reblozyl |
| Daiichi Sankyo INC. | $53.68 | 2024-2025 | Vanflyta, Datroway |
| Gilead Sciences, INC. | $45.42 | 2024-2025 | Trodelvy |
| Array Biopharma INC | $44.83 | 2024-2025 | Mektovi, Lorbrena, Xalkori |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $42.49 | 2024-2025 | Keytruda, Welireg |
| Genentech USA, INC. | $41.67 | 2023-2024 | Alecensa, Rozlytrek, Tecentriq |
| Bayer Healthcare Pharmaceuticals INC. | $37.67 | 2025 | |
| Pfizer INC. | $37.43 | 2025 | |
| Karyopharm Therapeutics INC. | $37.39 | 2024-2025 | Xpovio |
| Emd Serono, INC. | $35.21 | 2023-2025 | Bavencio |
| Inari Medical, INC. | $33.27 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Springworks Therapeutics, INC. | $29.39 | 2025 | Ogsiveo |
| Geron Corporation | $27.25 | 2025 | Rytelo |
| Adaptive Biotechnologies Corporation | $24.71 | 2024 | Clonoseq |
| Regeneron Healthcare Solutions, INC. | $24.35 | 2025 | Libtayo |
| Nuvation Bio INC. | $23.99 | 2025 | Ibtrozi |
| Genmab U.S., INC. | $23.96 | 2025 | Epkinly |
| Abiomed | $20.68 | 2024 | Impella |
| Abbvie INC. | $20.40 | 2025 | |
| Alexion Pharmaceuticals, INC. | $19.37 | 2024 | Ultomiris |
| Jazz Pharmaceuticals INC. | $18.70 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.